KRW 96700.0
(-6.84%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 196.83 Million KRW | -1.0% |
2022 | 198.81 Million KRW | -26.51% |
2021 | 270.54 Million KRW | -5.22% |
2020 | 285.44 Million KRW | -85.88% |
2019 | 2.02 Billion KRW | 167.84% |
2018 | 754.7 Million KRW | -19.38% |
2017 | 936.13 Million KRW | 113.18% |
2016 | 439.13 Million KRW | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 209.72 Million KRW | -35.45% |
2024 Q1 | 324.91 Million KRW | 65.07% |
2023 Q1 | 171.29 Million KRW | -13.84% |
2023 Q4 | 196.83 Million KRW | 19.51% |
2023 Q3 | 164.69 Million KRW | -13.06% |
2023 Q2 | 189.43 Million KRW | 10.59% |
2023 FY | 196.83 Million KRW | -1.0% |
2022 Q3 | 198.02 Million KRW | -26.45% |
2022 Q4 | 198.81 Million KRW | 0.4% |
2022 Q2 | 269.22 Million KRW | 37.67% |
2022 Q1 | 195.56 Million KRW | -27.72% |
2021 Q3 | 221.53 Million KRW | 0.0% |
2021 Q4 | 270.54 Million KRW | 22.12% |
Name | Inventory | Inventory Difference |
---|---|---|
HLB Co., Ltd. | 11.42 Billion KRW | 98.277% |
iNtRON Biotechnology, Inc. | 1.01 Billion KRW | 80.533% |
BINEX Co., Ltd. | 28.26 Billion KRW | 99.304% |
Bioneer Corporation | 41.35 Billion KRW | 99.524% |
Anterogen.Co.,Ltd. | 1.91 Billion KRW | 89.697% |
MEDIPOST Co., Ltd. | 14.51 Billion KRW | 98.644% |
CrystalGenomics, Inc. | 1.55 Billion USD | 87.34% |
Helixmith Co., Ltd | 914.11 Million KRW | 78.467% |
Chabiotech Co.,Ltd. | 34.11 Billion KRW | 99.423% |
Medy-Tox Inc. | 59.61 Billion KRW | 99.67% |
Peptron, Inc. | 172.18 Million KRW | -14.314% |
Amicogen, Inc. | 46.83 Billion KRW | 99.58% |
Genexine, Inc. | 3.8 Billion KRW | 94.83% |
HLB Therapeutics Co.,Ltd. | 5.33 Billion KRW | 96.311% |
ALTEOGEN Inc. | 1.06 Billion KRW | 81.576% |
PharmaResearch Co., Ltd. | 50.23 Billion KRW | 99.608% |
SillaJen, Inc. | 1.21 Billion KRW | 83.768% |
JETEMA, Co., Ltd. | 12.74 Billion KRW | 98.455% |
OliX Pharmaceuticals,Inc | 468.4 Million KRW | 57.978% |
Genomictree Inc. | 496.53 Million KRW | 60.358% |
MedPacto, Inc. | 620.00 KRW | -31747382.742% |
D&D Pharmatech | 3.45 Billion KRW | 94.295% |
EASY BIO,Inc. | 25.93 Billion KRW | 99.241% |
GI Innovation, Inc. | - KRW | -Infinity% |